• email
  • rss
  • twitter
  • facebook
  • linkedin
  • News
  • Investors
  • Contact

Ceapro Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Quality Management System
    • Sustainability
  • Technologies
    • Overview
    • Ethanol Fractionation Processes
    • Pressurized Gas Expanded (PGX) Technology
    • Chromatography Purification
    • Intellectual Property
    • Scientific Publications
  • Pipeline
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
    • Product Brochures
  • Cosmeceuticals
    • Overview
  • Nutraceuticals
    • Overview
    • Oat Beta Glucan
    • Avenanthramides
  • Business Development
    • Overview
    • Partners
  • News
  • Investors
  • Contact
  • Home
  • Investors
  • News / Events
  • Press Releases
Navigation
  • Overview
  • News / Events
    • Press Releases
    • Events
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • Corporate Governance
  • SEDAR
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007

Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference

March 23, 2023

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

March 8, 2023

Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company

February 21, 2023

Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event

January 10, 2023

Ceapro Announces Grant of Stock Options

January 4, 2023

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

December 22, 2022

Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

November 9, 2022

Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

November 7, 2022

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

October 13, 2022

Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update

August 24, 2022

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
  • Next »

Sign up for email ALERTS Be the first to receive news and updates on Ceapro. Sign Up

  • © 2023 Ceapro Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap